5 Key Takeaways

• 1

  Riad Sherif, MD, discussed neuroprotection as a potential next frontier in retinal therapeutics at the 2026 ASRS Meeting.

• 2

  Oculis is developing privosegtor for the restorative treatment of optic neuritis, an inflammatory condition affecting the optic nerve.

• 3

  Optic neuritis primarily affects young adults, averaging 32 years old, with about two-thirds of patients being women.

• 4

  The ongoing PIONEER-1 study is evaluating privosegtor, which previously showed promising results in the ACUITY trial.

• 5

  Privosegtor improved vision by approximately 18 letters at month 3 and preserved retinal structure by maintaining GCIPL.